高级检索
当前位置: 首页 > 详情页

Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 统计源期刊 ◇ 卓越:领军期刊 ◇ 中华系列

机构: [1]Translational Chinese Medicine Key Laboratory of Sichuan, Sichuan-Chongqing Joint Key Laboratory of Innovation of New Drugs of Traditional Chinese Medicine, Sichuan Institute for Translational Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan 610041, China [2]Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China [3]Information Technology Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China [4]West China Sanya Hospital of Sichuan University, Sanya, Hainan 572000, China [5]Xiangya School of Public Health, Central South University, Changsha, Hunan 410013, China [6]Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA [7]Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, China.
出处:
ISSN:

关键词: 10 1007/s13659-025-00500-3

摘要:
Peptide-drug conjugates (PDCs) have emerged as a promising strategy in cancer therapy, offering improved therapeutic efficacy and reduced toxicity. Compared to antibody-drug conjugates (ADCs) and small molecule-drug conjugates (SMDCs), PDCs possess distinct advantages, such as lower immunogenicity, improved tumor penetration, and simpler synthesis. This review discusses the latest advancements in PDC design, including novel peptide targeting mechanisms, linker selection, and formulation improvements for increased stability. Additionally, it explores the expanding clinical applications of PDCs and examines their limitations. The aim of this review is to provide a comprehensive overview of current PDC progress and outline future directions for their role in cancer treatment.Copyright © 2025 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:内科
第一作者:
第一作者机构: [1]Translational Chinese Medicine Key Laboratory of Sichuan, Sichuan-Chongqing Joint Key Laboratory of Innovation of New Drugs of Traditional Chinese Medicine, Sichuan Institute for Translational Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan 610041, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:56486 今日访问量:0 总访问量:4732 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号